Dihexa

A metabolically stabilized angiotensin IV–derived peptidomimetic studied as an HGF/c-Met system probe in neuronal-culture, synaptogenesis, and rodent cognitive-model research.

Molecular Profile

Type
Synthetic peptidomimetic (modified tripeptide-like angiotensin IV analog)
Molecular formula
C27H44N4O5
Molecular weight
~504.66 g/mol
CAS number
1401708-83-5
Fatty acid chain
N-terminal hexanoyl cap (hexanoic acid)
Sequence
N-hexanoic-Tyr-Ile-(6)aminohexanoic amide
Modification
N-terminal hexanoyl cap replacing the N-terminal residue of norleucine1-AngIV; C-terminal 6-aminohexanoic amide moiety replacing the His-Pro-Phe segment; designed to eliminate peptidase-sensitive bonds and increase metabolic stability and blood-brain-barrier permeance.

Mechanism & Target Class

Dihexa is a peptidomimetic in the angiotensin IV (AngIV) analog class, engineered from norleucine1-angiotensin IV by retaining the Tyr-Ile pharmacophore identified as the procognitive core and replacing peptidase-labile termini with an N-terminal hexanoyl cap and a C-terminal 6-aminohexanoic amide. These modifications confer increased hydrophobicity, metabolic stability, and blood-brain-barrier permeability. Mechanistic studies proposed that Dihexa acts at the level of the hepatocyte growth factor (HGF)/c-Met receptor tyrosine kinase system — specifically at HGF dimerization and availability — with downstream readouts examined in PI3K/Akt and MAPK/ERK signaling. Historically, the parent AngIV system was associated with the AT4 binding site, later identified as insulin-regulated aminopeptidase (IRAP); the shift toward an HGF/c-Met framing is a contested element of the literature, and the key papers asserting direct HGF binding were subsequently retracted.

Storage & Handling

Lyophilized
Store dry and sealed; short term at 0–4 °C, long term at −20 °C.
Handling
Dry compound reported stable at ambient shipping temperatures for short periods. Batch molecular weight may vary with degree of hydration. For research use only.

Primary Database

PubChem CID 129010512 ↗

References (21)

  1. Reviews

    1

    Hallberg M, et al. (2020). Frontiers in Pharmacology

    DOI: 10.3389/fphar.2020.590855PubMed 33178027

  2. 2

    Wright JW, Kawas LH, Harding JW. (2015). Progress in Neurobiology

    DOI: 10.1016/j.pneurobio.2014.11.004PubMed 25455861

  3. 3

    Wright JW, Harding JW. (2015). Journal of Alzheimer's Disease

    DOI: 10.3233/JAD-142814PubMed 25649658

  4. 4

    Ho JK, Nation DA. (2018). Neurosci Biobehav Rev

    DOI: 10.1016/j.neubiorev.2018.05.005PubMed 29733881

  5. 5

    Wright JW, Kawas LH, Harding JW. (2013). Front Endocrinol (Lausanne)

    DOI: 10.3389/fendo.2013.00158PubMed 24298267

  6. 6

    Wright JW, Harding JW. (2019). J Alzheimers Dis

    DOI: 10.3233/JAD-181035PubMed 30664507

  7. Clinical

    7

    Hua X, Church K, Walker W, et al. (2022). Journal of Alzheimer's Disease

    DOI: 10.3233/JAD-215511PubMed 35180125NCT03298672

  8. Primary research

    8

    Martino KA, Nakhre A, Demarest RM, Devilbiss DM. (2025). Neurotrauma Reports

    DOI: 10.1089/neur.2025.0053

  9. 9

    Kawas LH, McCoy AT, Yamamoto BJ, Wright JW, Harding JW. (2025). Journal of Pharmacology and Experimental Therapeutics

    DOI: 10.1016/j.jpet.2025.103566PubMed 40312092

  10. 10

    Benoist CC, Kawas LH, Zhu M, et al. (2025). Journal of Pharmacology and Experimental Therapeutics

    DOI: 10.1016/j.jpet.2025.103567PubMed 40312093

  11. 11

    Sun X, Deng Y, Fu X, Wang S, Duan R, Zhang Y. (2021). Brain Sciences

    DOI: 10.3390/brainsci11111487PubMed 34827486

  12. 12

    Weiss JB, Phillips CJ, Malin EW, Gorantla VS, Harding JW, Salgar SK. (2021). Annals of Medicine and Surgery

    DOI: 10.1016/j.amsu.2021.102917PubMed 34703584

  13. 13

    Uribe PM, Kawas LH, Harding JW, Coffin AB. (2015). Frontiers in Cellular Neuroscience

    DOI: 10.3389/fncel.2015.00003PubMed 25674052

  14. 14

    Benoist CC, Kawas LH, Zhu M, et al. (2014). Journal of Pharmacology and Experimental Therapeutics

    DOI: 10.1124/jpet.114.218735PubMed 25187433

  15. 15

    McCoy AT, Benoist CC, Wright JW, Kawas LH, et al. (2013). Journal of Pharmacology and Experimental Therapeutics

    DOI: 10.1124/jpet.112.199497PubMed 23055539

  16. 16

    Kawas LH, McCoy AT, Yamamoto BJ, Wright JW, Harding JW. (2012). Journal of Pharmacology and Experimental Therapeutics

    DOI: 10.1124/jpet.111.188136PubMed 22129598

  17. 17

    Kawas LH, Yamamoto BJ, Wright JW, Harding JW. (2011). Journal of Pharmacology and Experimental Therapeutics

    DOI: 10.1124/jpet.111.185694PubMed 21859930

  18. 18

    Benoist CC, Wright JW, Zhu M, Appleyard SM, Wayman GA, Harding JW. (2011). Journal of Pharmacology and Experimental Therapeutics

    DOI: 10.1124/jpet.111.182220PubMed 21719467

  19. 19

    Yamamoto BJ, Elias PD, Masino JA, et al. (2010). Journal of Pharmacology and Experimental Therapeutics

    PubMed 20086056

  20. 20

    Lew RA, Mustafa T, Ye S, McDowall SG, Chai SY, Albiston AL. (2003). Journal of Neurochemistry

    DOI: 10.1046/j.1471-4159.2003.01852.xPubMed 12871575

  21. 21

    Albiston AL, McDowall SG, Matsacos D, et al. (2001). Journal of Biological Chemistry

    DOI: 10.1074/jbc.C100512200